BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.
Funding
$48.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ischemic cardiomyopathy leads to congestive heart failure due to the enlargement and impaired function of the left ventricle. Current treatments do not directly address the anatomical damage to the heart muscle, limiting their effectiveness in restoring cardiac function.
Solution
BioVentrix develops surgical equipment designed to restore the size and function of the left ventricle in patients with ischemic cardiomyopathy. Their technology aims to directly address the anatomical damage caused by the disease, improving cardiac function and potentially slowing the progression of heart failure. By reshaping the left ventricle, the device helps the heart pump more efficiently, leading to improved patient outcomes.
Target Audience
The primary target audience includes cardiac surgeons and patients suffering from heart failure due to ischemic cardiomyopathy.
Features
- Surgical device for left ventricular restoration.
- Aims to improve cardiac function in patients with ischemic cardiomyopathy.
- Addresses anatomical damage to the heart muscle.